Iloprost

Iloprost
Clinical data
Trade namesVentavis, Ilomedine, Aurlumyn
AHFS/Drugs.comMonograph
MedlinePlusa612032
License data
Routes of
administration
Inhalation, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNot determined[1]
Protein binding60%[1]
MetabolismVia β-oxidation to inactive tetranor-iloprost[1]
Elimination half-life20–30 minutes[1]
ExcretionKidney (68%) and fecal (12%)[1]
Identifiers
  • 5-{(E)-(1S,5S,6R,7R)-7-hydroxy-6[(E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl]-bicyclo[3.3.0]octan-3-ylidene}pentanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.163.887 Edit this at Wikidata
Chemical and physical data
FormulaC22H32O4
Molar mass360.494 g·mol−1
3D model (JSmol)
  • CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O
  • InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1 ☒N
  • Key:HIFJCPQKFCZDDL-ACWOEMLNSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues.[4] Iloprost is a prostacyclin mimetic.[1]

For pulmonary arterial hypertension, iloprost is given via inhalation. Iloprost works by opening (dilating) the blood vessels to allow the blood to flow through them. It was developed by the pharmaceutical company Schering AG and is marketed by Bayer Schering Pharma AG in the European Union and by Actelion Pharmaceuticals in the US.

  1. ^ a b c d e f g "Ventavis- iloprost solution". DailyMed. 26 July 2022. Archived from the original on 19 February 2024. Retrieved 19 February 2024.
  2. ^ "Aurlumyn- iloprost injection, solution". DailyMed. 11 March 2024. Retrieved 6 May 2024.
  3. ^ "Ventavis EPAR". European Medicines Agency (EMA). 26 August 2013. Archived from the original on 12 November 2020. Retrieved 19 February 2024.
  4. ^ "Iloprost Information" (PDF). Archived from the original (PDF) on 6 April 2016. Retrieved 5 February 2009.